Eddit

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(148 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 
__NOTOC__
 
__NOTOC__
 
*'''[[Further reading]]'''
 
*'''[[Further reading]]'''
 +
  
 
*'''[[Unproven ideas]]'''
 
*'''[[Unproven ideas]]'''
 +
 
*'''[[Reviews on covid19 disease]]'''
 
*'''[[Reviews on covid19 disease]]'''
 +
*'''[[Clinical guidelines and advice]]'''
  
*'''[[Research tools]]'''
 
{{tp|p=32142596|t=2020. Machine Learning, COVID?19 (2019?nCoV), and multi?OMICS |pdf=|usr=}}
 
{{tp|p=32187834|t=2020. ..COVID19: Cytometry and the New Challenge for Global Health |pdf=|usr=}}
 
{{tp|p=32270412|t=ä. Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2 |pdf=|usr=}}
 
  
*
 
*'''[[Structure of covid19]]'''
 
  
*'''[[Target binding and uptake]]'''
+
*'''[[Respiration mgmt]]'''
{{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
+
{{tp|p=32336612|t=ä. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32210742|t=2020. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis |pdf=|usr=}}
+
{{tp|p=32327200|t=ä. Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research |pdf=|usr=}}
+
  
 +
*'''[[Diagnosis (Laboratory)]]'''
  
  
 +
*'''[[Diagnosis (Lung CT, Sonography)]]'''
 +
 +
*'''[[Diagnosis (other modalities)]]'''
 +
 +
 +
 +
 +
*'''[[Structure of covid19]]'''
 +
 +
 +
*'''[[Target binding and uptake]]'''
 
*'''[[Cytopathic effects]]'''
 
*'''[[Cytopathic effects]]'''
 
*'''[[Secretion and shedding]]'''
 
*'''[[Secretion and shedding]]'''
{{tp|p=32271376|t=ä. Factors associated with prolonged viral RNA shedding in patients with COVID-19 |pdf=|usr=}}
+
 
 +
 
  
 
*'''[[Innate sensing]]'''
 
*'''[[Innate sensing]]'''
 +
 
*'''[[Immunology]]'''
 
*'''[[Immunology]]'''
{{tp|p=32348472|t=ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?|pdf=|usr=}}
 
 
  
 
*'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]'''
 
*'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]'''
  
  
*'''[[Microvascular]]'''
+
 
*
+
*'''[[Pathobiology]]'''
 +
 
 +
 
 +
*'''[[Disease Models]]'''
 +
 
 +
 
 +
*'''[[Similar diseases and pathomechanisms]]'''
 +
 
 +
 
 +
 
 +
 
 
*'''[[Early symptoms]]'''
 
*'''[[Early symptoms]]'''
{{tp|p=32371463|t=2020. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis |pdf=|usr=}}
 
  
 
*'''[[Systemic disease, any manifestations]]'''
 
*'''[[Systemic disease, any manifestations]]'''
{{tp|p=32368495|t=2020. Co-infection with SARS-CoV-2 and influenza A virus |pdf=|usr=}}
 
{{tp|p=32368493|t=2020. Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report |pdf=|usr=}}
 
{{tp|p=32317036|t=ä. Bacterial and fungal infections in COVID-19 patients: A matter of concern |pdf=|usr=}}
 
  
 
*'''[[Co-Infection]]'''
 
*'''[[Co-Infection]]'''
  
*'''[[ARDS]]'''
 
{{tp|p=32153144|t=2020. COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis |pdf=|usr=}}
 
{{tp|p=32342675|t=2020. COVID-19, A and Hypersensitivity Pneumonitis |pdf=|usr=}}
 
  
 
*'''[[Pulmonary embolism, coagulation]]'''
 
*'''[[Pulmonary embolism, coagulation]]'''
 +
 +
 +
  
  
 
*'''[[Hematology]]'''
 
*'''[[Hematology]]'''
{{tp|p=32342677|t=2020. Severe Thrombocytopenia in a Patient with COVID-19 |pdf=|usr=}}
 
  
*'''[[Heart]]'''
 
  
*'''[[Neurology, ophthalmology, orl]]'''
 
  
*'''[[Dermatology]]'''
+
*'''[[Heart]]'''
  
*'''[[Gastroenterology, hepatology]]'''
 
{{tp|p=32188528|t=ä. SARS-CoV-2 enterocolitis with persisting to excrete the virus for approximately two weeks after recovering from diarrhea: A case report |pdf=|usr=}}
 
{{tp|p=32252855|t=ä. Alert for SARS-CoV-2 infection caused by fecal aerosols in rural areas in China |pdf=|usr=}}
 
  
  
*'''[[Kidney, urology]]==
+
*'''[[Neurology, ophthalmology, orl]]'''
{{tp|p=32299479|t=2020. Acute kidney injury in SARS-CoV-2 infected patients |pdf=|usr=}}
+
{{tp|p=32197060|t=2020. Rhabdomyolysis as Potential Late Complication Associated with COVID-19 |pdf=|usr=}}
+
  
  
*
 
*'''[[Pathobiology]]'''
 
{{tp|p=32317509|t=2020. COVID-19 and lung pathology |pdf=|usr=}}
 
{{tp|p=32345362|t=2020. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues |pdf=|usr=}}
 
{{tp|p=32333601|t=ä. Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients  With IBD |pdf=|usr=}}
 
  
 +
*'''[[Dermatology]]'''
  
*'''[[Disease Models]]'''
 
{{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
 
{{tp|p=32378471|t=2020. Animal models for emerging coronavirus: progress and new insights |pdf=|usr=}}
 
  
  
*'''[[Similar diseases and pathomechanisms]]'''
+
*'''[[Gastroenterology, hepatology]]'''
{{tp|p=31859605|t=2020. Genetic manipulation of porcine deltacoronavirus reveals insights into NS6 and NS7 functions: a novel strategy for vaccine design |pdf=|usr=}}
+
{{tp|p=32186278|t=2020. Influenza-associated pneumonia as reference to assess seriousness of coronavirus  disease (COVID-19) |pdf=|usr=}}
+
{{tp|p=32142938|t=2020. Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated  with evolution of 2019-nCoV |pdf=|usr=}}
+
  
 +
*'''[[Kidney, urology]]'''
  
*
+
*'''[[The morbid survivor]]'''
*'''[[Diagnosis (Laboratory)]]'''
+
  
 +
*'''[[Risk and special populations]]'''
  
*'''[[Diagnosis (Lung CT, Sonography)]]'''
 
  
*'''[[Diagnosis (other modalities)]]'''
 
{{tp|p=32276598|t=2020. Using echocardiography to guide the treatment of novel coronavirus pneumonia |pdf=|usr=}}
 
  
*'''[[Respiration mgmt]]'''
+
*'''[[Case reports]]'''
 +
 
  
  
*'''[[Clinical guidelines and advice]]'''
 
  
*'''[[Risk and special populations]]'''
 
  
*'''[[Case reports]]'''
 
  
  
Zeile 111: Zeile 100:
  
  
*'''[[The morbid survivor]]'''
+
*'''[[Registries]]'''
 
+
  
  
 
*'''[[Trials]]'''
 
*'''[[Trials]]'''
{{tp|p=C7102592|t=ä. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID) |pdf=|usr=}}
 
  
 
*'''[[Candidate Compounds Covid19]]'''
 
*'''[[Candidate Compounds Covid19]]'''
  
*'''[[Biophysics of aerosols]]'''
 
  
 
*'''[[Other routes of infection]]'''
 
*'''[[Other routes of infection]]'''
 +
 +
 +
*'''[[Biophysics of aerosols]]'''
 +
 +
 +
  
 
*'''[[Passive protective equipment]]'''
 
*'''[[Passive protective equipment]]'''
 +
 +
 +
 
*'''[[Running your hospital]]'''
 
*'''[[Running your hospital]]'''
*'''[[Mental aspects of health professionals]]'''
 
  
 +
 +
*'''[[Mental aspects of health professionals]]'''
  
 
*'''[[Socio-psychiatric aspects of the status hygienicus]]'''
 
*'''[[Socio-psychiatric aspects of the status hygienicus]]'''
 +
 +
 +
  
 
*'''[[Avoiding clinical medicine in other diseases]]'''
 
*'''[[Avoiding clinical medicine in other diseases]]'''
 +
  
  
 
*'''[[Occupational medicine, workplace security and status hygienicus]]'''
 
*'''[[Occupational medicine, workplace security and status hygienicus]]'''
{{tp|p=32341630|t=2020. Tackling Corona Virus Disease 2019 (COVID 19) in Workplaces |pdf=|usr=}}
+
 
  
 
*'''[[Economic aspects of the status hygienicus]]'''
 
*'''[[Economic aspects of the status hygienicus]]'''
 
  
  
 
*'''[[Educational aspects of the status hygienicus]]'''
 
*'''[[Educational aspects of the status hygienicus]]'''
*
+
----
 +
 
 +
 
 
*'''[[Host, vector, one health, atmospheric aspects]]'''
 
*'''[[Host, vector, one health, atmospheric aspects]]'''
  
 
*'''[[Origin of Covid19]]'''
 
*'''[[Origin of Covid19]]'''
 +
 +
*'''[[Epidemiology]]'''
 +
 +
 +
 +
  
 
*'''[[Remission, recurrence and persistence]]'''
 
*'''[[Remission, recurrence and persistence]]'''
{{tp|p=32183934|t=2020. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020 |pdf=|usr=}}
 
  
*'''[[Epidemiology]]'''
+
 
*'''[[Failure of politics and public health guidance]]'''
+
{{tp|p=32363133|t=ä. The Inadequacy of Regulatory Frameworks in Time of Crisis and in Low-Resource Settings: Personal Protective Equipment and COVID-19 |pdf=|usr=}}
+
{{tp|p=32241306|t=ä. Harmonizing the COVID-19 cacophony: People need guidance |pdf=|usr=}}
+
{{tp|p=32143519|t=2020. Prediction of Epidemic Spread of the 2019 Novel Coronavirus Driven by Spring Festival Transportation in China: A Population-Based Study |pdf=|usr=}}
+
  
 
*'''[[Failure of executive measures]]'''
 
*'''[[Failure of executive measures]]'''
 +
----
 +
*'''[[Failure of politics and public health guidance]]'''
 +
 +
 
*'''[[Political abuse of Covid19]]'''
 
*'''[[Political abuse of Covid19]]'''
 +
 +
  
 
*'''[[Lost people]]'''
 
*'''[[Lost people]]'''
{{tp|p=32358774|t=ä. On the death of 100?+?Italian doctors from COVID-19 |pdf=|usr=}}
 
{{tp|p=32226292|t=2020. Tribute to health workers in China: A group of respectable population during the  outbreak of the COVID-19 |pdf=|usr=}}
 
  
 
*'''[[Lost civilization]]'''
 
*'''[[Lost civilization]]'''
{{tp|p=32345850|t=2020. Collateral damage of the COVID-19 outbreak: expression of concern |pdf=|usr=}}
 
  
*'''[[History of covid19 exploration]]'''
+
----
{{tp|p=32235575|t=2020. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment |pdf=|usr=}}
+
  
*'''[[Current state of coviki.org]]'''
+
 
*[[PubMed selected papers unsorted to be listed in contents topics]]
+
*'''[[History of covid19 exploration]]'''
*[[coviki state of development]]
+
 
*'''[[misc.]]'''
 
*'''[[misc.]]'''
{{tp|p=32319220|t=2020. Covid-19 and Namaste |pdf=|usr=}}
+
 
 +
 
 +
*'''[[Research tools]]'''
 +
 
 +
 
 +
 
 +
 
 +
{{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}}
 +
{{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}}
 +
 
 +
 
 +
*'''[[PrePrint scene]]'''
 +
 
 +
 
 
*'''[[from the ads]]'''
 
*'''[[from the ads]]'''
*[http://www.okaybio.com covid19 antibodies, proteins & reagents]
+
 
*[http://www.reactionbiology.com 700 kinsse assays]
+
*'''[[Current state of coviki.org]]'''
*[http://www.neuroindx.com tissue microdissection device]
+
*'''[[on-topic personal thoughts]]'''

Aktuelle Version vom 7. Juni 2020, 22:19 Uhr



















































27490990 2017. AVCpred: an integrated web server for prediction and design of antiviral compounds
25040500 2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system



Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis